Tag:
Biomira
Latest Headlines
Latest Headlines
SPOTLIGHT: Biomira bound for USA
Canada's Biomira plans to reincorporate in the U.S., headquartering its parent company in Seattle. CEO Robert Kirkman says the relocation to the U.S. will raise the company's profile in U.S.
C&L: Hedegaard takes helm at Bavarian Nordic
Bavarian Nordic said Anders Hedegaard will assume the position of president and CEO of the group on August 1. Peter Wulff will transfer to the position of executive vice president of business
ALSO NOTED: Daiichi Sankyo files supplemental NDA; BioSante launches Phase III trial; and much more...
> Daiichi Sankyo has filed a supplemental NDA with the FDA, looking for approval to use WelChol to improve glycemic control. Report
> Antares Pharma's development partner, BioSante Pharmaceuticals, has initiated a Phase III safety and efficacy trial of Antares' transdermal testosterone gel for the treatment of FSD. …
ALSO NOTED: FDA staffers back Ketek; Abbott gains a majority of Kos shares; and much more...
> In advance of an FDA advisory committee meeting on the controversial antibiotic Ketek , agency staffers have concluded that the data on the Sanofi-Aventis therapy demonstrates that it is safe and effective. …
ALSO NOTED: Depomed surges on new data; FDA OKs Biomira study; and much more...
> Shares of Depomed surged on the news that a Phase II trial has produced data that demonstrates significantly reduced pain scores for patients taking one of two doses of its Gabapentin GR painkiller. Report
> Biomira and the FDA have agreed on a clinical trial design to test Stimuvax for advanced lung cancer. …
DEALS: Abbott buys Kos in $3.7B deal
Abbott buys Kos in $3.7B deal
Biomira expands its portfolio with ProlX buyout
Canada's Biomira has expanded its oncology portfolio with a deal to buy ProlX Pharmaceuticals for cash and stock worth a collective $23.9 million. Up to $15 million in additional Biomira stock will be paid for achieving certain milestones. The acquisition will give Biomira control of Stimuvax, a synthetic MUC1 peptide vaccine now in Phase III, and PX-12, a thioredoxin inhibitor which is headed into Phase II. Two more …
C&L: Kirkman tapped to run Biomira
Canada's Biomira has named Robert L. Kirkman --formerly acting president and chief executive of biopharmaceutical company Xcyte Therapies--as president and chief executive.
Applied NeuroSolutions has appointed Ellen R. Hoffing as its president and CEO and a member of its board of directors, replacing John …
C&L: AnorMED CEO steps down
AnorMED announced today that Dr. Mike Abrams has stepped down as president and CEO, effective immediately. He has also resigned as a director of AnorMED. Dr. Abrams has served as the company's president and CEO since founding the company in 1996.
Alex McPherson has resigned from Biomira after 15 years as president and CEO. …
Biomira shares jump on cancer vaccine data
Shares of Canada's Biomira jumped 17 percent after the biotech announced positive survival data from a mid-stage trial of its cancer vaccine. Patients taking Stimuvax lived an average of 30.6 months compared to an average of 13.3 months for patients receiving supportive care alone. The study followed 171 patients with advanced lung cancer whose disease had been stabilized by chemotherapy. Biomira's collaborator on Stimuvax, Merck KGaA, plans to begin a pivotal trial in the summer.
- read the AP report on the trial data
